Search research articles
Contact Us
Filters
Showing results (91-100 of 128) with videos related to
Page
of 13
Sort By:
Cardiovascular Diabetology
|
October 5, 2021
Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes
Bradley Sarak, Subodh Verma, C David Mazer, et al.
European Heart Journal
|
August 31, 2025
Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial
Brady Park, Fallon Dennis, Arianna Z He, et al.
The Canadian Journal of Cardiology
|
June 16, 2010
Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada
Manoela Braga, Amparo Casanova, Hwee Teoh, et al.
Metabolism Open
|
August 20, 2020
Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
Vinay Garg, Subodh Verma, Kim A Connelly, et al.
The Journal of Biological Chemistry
|
December 21, 2014
The essential autophagy gene ATG7 modulates organ fibrosis via regulation of endothelial-to-mesenchymal transition
Krishna K Singh, Fina Lovren, Yi Pan, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
July 29, 2008
Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis
Fina Lovren, Yi Pan, Adrian Quan, et al.
Cardiovascular Endocrinology & Metabolism
|
June 29, 2026
Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trial
Wei-Siang Chen, Ning-I Yang, Subodh Verma, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
September 29, 2023
Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling
Ehab Bakbak, Subodh Verma, Aishwarya Krishnaraj, et al.
European Journal of Preventive Cardiology
|
March 31, 2026
Relationship Between Achieved LDL-C and Saphenous Vein Graft Patency: A Post Hoc Analysis of the NEWTON-CABG CardioLink-5 Study
Michael Szarek, Lawrence A Leiter, Hwee Teoh, et al.
The Annals of Thoracic Surgery
|
September 30, 2023
Association of Cerebral Oximetry With Brain Ischemic Lesions and Functional Outcomes in Arch Repair
Makoto Hibino, Mark D Peterson, Ricardo Tachibana, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 128) with videos related to
Sort By:
Page
of 13
Cardiovascular Diabetology
|
October 5, 2021
Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes
Bradley Sarak, Subodh Verma, C David Mazer, et al.
European Heart Journal
|
August 31, 2025
Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial
Brady Park, Fallon Dennis, Arianna Z He, et al.
The Canadian Journal of Cardiology
|
June 16, 2010
Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada
Manoela Braga, Amparo Casanova, Hwee Teoh, et al.
Metabolism Open
|
August 20, 2020
Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
Vinay Garg, Subodh Verma, Kim A Connelly, et al.
The Journal of Biological Chemistry
|
December 21, 2014
The essential autophagy gene ATG7 modulates organ fibrosis via regulation of endothelial-to-mesenchymal transition
Krishna K Singh, Fina Lovren, Yi Pan, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
July 29, 2008
Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis
Fina Lovren, Yi Pan, Adrian Quan, et al.
Cardiovascular Endocrinology & Metabolism
|
June 29, 2026
Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trial
Wei-Siang Chen, Ning-I Yang, Subodh Verma, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
September 29, 2023
Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling
Ehab Bakbak, Subodh Verma, Aishwarya Krishnaraj, et al.
European Journal of Preventive Cardiology
|
March 31, 2026
Relationship Between Achieved LDL-C and Saphenous Vein Graft Patency: A Post Hoc Analysis of the NEWTON-CABG CardioLink-5 Study
Michael Szarek, Lawrence A Leiter, Hwee Teoh, et al.
The Annals of Thoracic Surgery
|
September 30, 2023
Association of Cerebral Oximetry With Brain Ischemic Lesions and Functional Outcomes in Arch Repair
Makoto Hibino, Mark D Peterson, Ricardo Tachibana, et al.
Page
of 13